Cypress Bioscience of San Diego, California has aquired worldwide licensing rights for Alexza Pharmaceutical’s Staccato Nicotine inhaler for smoking cessation. Alexza will receive $5 million up front, with another $1 million due upon meeting preclinical and clinical milestones. Read the company’s press release.
Cypress also announced that it purchased rights to an intranasal carbetocin product for the treatment of autism from Marina Biotech. Marina, formerly MDRNA, formerly Nastech, has completed Phase I studies of the formulation. The deal may eventually be worth up to $28 million. Read the company’s press release.
Cypress Bioscience licenses two OINDPs
published on
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
